{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:23:15Z","timestamp":1791685395508,"version":"4.3.4"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Magnetic Resonance Imaging"],"published-print":{"date-parts":[[2023,10]]},"abstract":"\n Background<\/jats:title>\n \n MRI is crucial in diagnosing hepatocellular carcinoma (HCC). Superparamagnetic iron oxide particles (SPIO) are liver\u2010specific contrast agents which enhance lesions in T\n 2<\/jats:sub>\n \u2010weighted images. Iron oxide nano\u2010particle m\u2010PEG\u2010silane (IOP) Injection, a newly developed SPIO, showed promising imaging effects and good safety profile in preclinical studies and in phase I clinical trial.\n <\/jats:p>\n <\/jats:sec>\n \n Purpose<\/jats:title>\n To evaluate the safety and clinical validity of IOP Injection as MRI contrast agent in diagnosing HCC.<\/jats:p>\n <\/jats:sec>\n \n Study type<\/jats:title>\n Prospective.<\/jats:p>\n <\/jats:sec>\n \n Subjects<\/jats:title>\n A total of 52 subjects (61.6\u00a0\u00b1\u200911.05\u2009years, 45 males\/7 females) with suspected HCC.<\/jats:p>\n <\/jats:sec>\n \n Field Strength\/Sequence<\/jats:title>\n \n 1.5\u00a0T<\/jats:styled-content>\n ,\n \n T\n 1<\/jats:sub>\n <\/jats:styled-content>\n \u2010weighted in\/opposed phase,\n \n T\n 2<\/jats:sub>\n <\/jats:styled-content>\n *\u2010weighted gradient echo,\n \n T\n 2<\/jats:sub>\n <\/jats:styled-content>\n \u2010weighted fast spin echo, true fast imaging with steady\u2010state free precession.\n <\/jats:p>\n <\/jats:sec>\n \n Assessment<\/jats:title>\n Adverse effects and clinical monitoring were recorded throughout the 5\u2010day study. Two independent readers (M.G.H. with 30\u2009years of experience, S.P.K. with 26\u2009years of experience) made the diagnosis. The diagnostic performance of IOP\u2010enhanced MRI was evaluated with sensitivity and positive predictive value by comparing to the pathology reports from subsequent hepatic resection. The number of lesions with various sizes and degrees of differentiation detected by IOP\u2010enhanced MRI was assessed. The relative change in signal intensities over time was indirectly measured from acquired images.<\/jats:p>\n <\/jats:sec>\n \n Statistical Tests<\/jats:title>\n Sensitivity and positive predictive value were used to evaluate the diagnostic performance of IOP\u2010enhanced MRI. Prevalence\u2010adjusted and bias\u2010adjusted \ud835\udf05 coefficient was used to assess the interreader variability.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n No serious adverse event related to IOP Injection was found. IOP Injection enhanced the lesion\u2010to\u2010liver contrast ratio in T\n 2<\/jats:sub>\n *\u2010weighted images by 50.1%\u00a0\u00b1\u20094.8%. IOP\u2010enhanced MRI detected HCC with 100% sensitivity by subject and 96% sensitivity by lesion. IOP Injection visualized subtle vascular invasion as filling defect within vessels in true fast imaging with steady\u2010state free precession (TrueFISP) images.\n <\/jats:p>\n <\/jats:sec>\n \n Data Conclusion<\/jats:title>\n IOP Injection was safe and efficacious as MRI contrast agent in diagnosing HCC in a limited group of subjects.<\/jats:p>\n <\/jats:sec>\n \n Evidence Level<\/jats:title>\n 2.<\/jats:p>\n <\/jats:sec>\n \n Technical Efficacy<\/jats:title>\n Stage 2.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/jmri.28645","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T09:00:20Z","timestamp":1676106020000},"page":"1177-1188","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["IOP<\/scp>\n Injection, A Novel Superparamagnetic Iron Oxide Particle\n MRI<\/scp>\n Contrast Agent for the Detection of Hepatocellular Carcinoma: A Phase\n II<\/scp>\n Clinical Trial"],"prefix":"10.1002","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0605-2800","authenticated-orcid":false,"given":"Chi\u2010Feng","family":"Chiang","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering National Taiwan University Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan\u2010Hung","family":"Hsu","sequence":"additional","affiliation":[{"name":"MegaPro Biomedical Co. Ltd. Zhubei City, Hsinchu County Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen\u2010Yuan","family":"Hsieh","sequence":"additional","affiliation":[{"name":"MegaPro Biomedical Co. Ltd. Zhubei City, Hsinchu County Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu\u2010Hsin","family":"Liao","sequence":"additional","affiliation":[{"name":"MegaPro Biomedical Co. Ltd. Zhubei City, Hsinchu County Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih\u2010Lung","family":"Chen","sequence":"additional","affiliation":[{"name":"MegaPro Biomedical Co. Ltd. Zhubei City, Hsinchu County Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung\u2010Chu","family":"Chen","sequence":"additional","affiliation":[{"name":"MegaPro Biomedical Co. Ltd. Zhubei City, Hsinchu County Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po\u2010Chin","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging National Taiwan University Hospital Taipei Taiwan"},{"name":"Department of Medical Imaging National Taiwan University Hospital Hsinchu Branch Hsinchu Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shian\u2010Jy","family":"Wang","sequence":"additional","affiliation":[{"name":"MegaPro Biomedical Co. Ltd. Zhubei City, Hsinchu County Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,11]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2020.10.001"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.14140690"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics5030383"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i14.4334"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.08.065"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.5152\/dir.2014.13370"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29487"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.24419"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.01.031"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.12.007"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)90018-V"},{"key":"e_1_2_5_14_1","first-page":"1","article-title":"The treatment of hepatocellular carcinoma with portal vein tumor thrombosis","volume":"40","author":"Qadan M","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.5152\/dir.2015.15125"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000481315"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/13651820410024058"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-002-1721-7"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.195.2.7724772"}],"container-title":["Journal of Magnetic Resonance Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmri.28645","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmri.28645","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmri.28645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:59:53Z","timestamp":1764691193000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmri.28645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,11]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/jmri.28645"],"URL":"https:\/\/doi.org\/10.1002\/jmri.28645","archive":["Portico"],"relation":{},"ISSN":["1053-1807","1522-2586"],"issn-type":[{"value":"1053-1807","type":"print"},{"value":"1522-2586","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,11]]},"assertion":[{"value":"2022-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}